GENFIT S A/ADR’s (NASDAQ:GNFT) lock-up period is set to end on Monday, September 23rd. GENFIT S A/ADR had issued 6,150,000 shares in its public offering on March 27th. The total size of the offering was $124,968,000 based on an initial share price of $20.32. After the expiration of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Several equities analysts have weighed in on the company. Zacks Investment Research lowered GENFIT S A/ADR from a “buy” rating to a “hold” rating in a report on Tuesday, September 10th. ValuEngine upgraded GENFIT S A/ADR from a “hold” rating to a “buy” rating in a report on Thursday, August 15th. Stifel Nicolaus assumed coverage on GENFIT S A/ADR in a report on Tuesday, June 25th. They set a “hold” rating on the stock. Finally, HC Wainwright set a $72.00 target price on GENFIT S A/ADR and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. GENFIT S A/ADR has a consensus rating of “Buy” and an average target price of $45.69.
GENFIT S A/ADR stock opened at $17.55 on Monday. The business has a 50-day simple moving average of $16.91. GENFIT S A/ADR has a 52 week low of $14.91 and a 52 week high of $26.25.
About GENFIT S A/ADR
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Featured Article: 12b-1 Fees
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.